News
-
-
-
PRESS RELEASE
Communiqué de presse : Dupixent, premier médicament biologique approuvé en Chine pour le traitement de la BPCO
Dupixent, premier médicament biologique approuvé en Chine pour le traitement de la BPCO, réduit les exacerbations et améliore la fonction respiratoire. Approbation suite à études de phase III -
PRESS RELEASE
Coinsilium Group Limited: UNAUDITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE SIX-MONTH PERIOD ENDED 30 JUNE 2024
Coinsilium Group Limited announces unaudited consolidated interim financial statements for the six-month period ended 30 June 2024. Revenue decreased, profit improved. Corporate agreements and investments made in Web3 projects. Directors' statement provided -
PRESS RELEASE
EQS-Adhoc: BayWa AG: Impairment tests lead to extraordinary depreciation of € 222.2 million (impairment tests in accordance with IAS 36)
BayWa AG reports non-cash impairment losses of €222.2 million in Half-Year Financial Statements 2024 due to impairment tests. BayWa r.e. AG is the most affected subsidiary -
-
-
PRESS RELEASE
Vossloh presents pioneering solutions for the rail infrastructure of the future at the leading trade fair InnoTrans 2024
Vossloh presents pioneering solutions for the rail infrastructure of the future at InnoTrans 2024, showcasing sustainable materials, digital solutions, and circular economy advancements -
-
PRESS RELEASE
EQS-Adhoc: The Platform Group AG: The Platform Group raises sales and earnings forecast for 2024 – Increase in medium-term planning
The Platform Group AG announces higher sales and earnings forecast for 2024, adjusting medium-term planning. Increased GMV, sales, EBITDA, and partners expected